Back to School: How biopharma can reboot drug development. Access exclusive analysis here

A need for speed

twoXAR's aims to slash lead prioritization time with disease-mapping algorithm

Bioinformatics play twoXAR Inc. aims to condense years of wet-lab compound discovery and lead prioritization into minutes. The company has created an in silico platform that uses machine learning to build a mathematical disease model and predict the efficacy of compounds in that disease.

twoXAR's computational platform, DUMA, is based on CEO Andrew A. Radin's work in biomedical informatics at Stanford University and serves as a drug discovery tool internally, to identify

Read the full 710 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE